erbB2 Overexpression in Uterine Serous Cancer: A Molecular Target for Trastuzumab Therapy
Endometrial cancer is the most common female genital tract malignancy in the United States. Type I endometrial cancer is usually diagnosed at an early stage, and has a good prognosis. Type II is very aggressive, and is responsible for most uterine cancer relapses and deaths. Uterine serous adenocarc...
Main Authors: | Karim S. ElSahwi, Alessandro D. Santin |
---|---|
Format: | Article |
Language: | English |
Published: |
Hindawi Limited
2011-01-01
|
Series: | Obstetrics and Gynecology International |
Online Access: | http://dx.doi.org/10.1155/2011/128295 |
Similar Items
-
Regression of metastatic, radiation/chemotherapy-resistant uterine serous carcinoma overexpressing HER2/neu with trastuzumab emtansine (TDM-1)
by: Alessandro D. Santin, et al.
Published: (2017-02-01) -
Mechanisms of Trastuzumab resistance in ErbB2-driven breast cancer and newer opportunities to overcome therapy resistance
by: Tameka A Bailey, et al.
Published: (2011-01-01) -
Experimental studies on ErbB targeted therapy in malignant melanoma
by: Severinsson, Emelie
Published: (2012) -
Analysis of ErbB Receptors: Regulation of ErbB-1 Kinase Activation and Localization of ErbB-4 to Membrane Microdomains
by: Thiel, Kristina Wyatt
Published: (2007) -
Targeting the Calmodulin-Regulated ErbB/Grb7 Signaling Axis in Cancer Therapy
by: Antonio Villalobo, et al.
Published: (2013-04-01)